Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 13Plasma cell 9Thoracic 2Other hematologic neoplasm 2CNS 2Breast 2Other solid neoplasm 1Myeloid 1Gynecologic 1Genitourinary 1Gastrointestinal 1

Conditions

Glioblastoma 1Craniopharyngioma 1Astrocytoma 1

Interventions

Magnetic Resonance Spectroscopy 73Temozolomide 68Specimen Handling 48Radiotherapy 40Radiosurgery 29Bevacizumab 26Radiation 25Cyclophosphamide 25Nivolumab 21Biopsy 21pembrolizumab 20Carboplatin 16X-Rays 14Lomustine 13Ipilimumab 13fludarabine 12Irinotecan 12Vincristine 11Topotecan 11Surgical Procedures, Operative 11Cisplatin 11Blood Specimen Collection 11trametinib 9dinutuximab 9Immunoglobulin G 8Etoposide 8Doxorubicin 8lutetium Lu 177 dotatate 7fludarabine phosphate 7atezolizumab 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
tocilizumab × CNS × 90 days × Clear all
NCT05233397 2026-04-23

ACTEMRA® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma

Nationwide Children's Hospital

Phase 2 Recruiting
30 enrolled
CNS

Craniopharyngioma

NCT04729959 2026-04-01

Testing the Addition of the Immune Therapy Drugs, Tocilizumab and Atezolizumab, to Radiation Therapy for Recurrent Glioblastoma

National Cancer Institute (NCI)

Phase 2 Active not recruiting
59 enrolled
CNS

Astrocytoma, Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡